Morphology of Rat Kidney and Thymus after Native and Antibody-Coupled Cyclosporin a Application (Reduced Toxicity of Targeted Drug)

Folia Microbiologica

Volumn 42, Issue 3, 1997, Pages 277-287

  Rossmann, P ^a   Rihova B ^a   Strohalm, J ^b   Ulbrich, K ^b  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^b INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ORYCTOLAGUS CUNICULUS;

ANTIBODY CONJUGATE; CYCLOSPORIN; CYCLOSPORIN DERIVATIVE; DRUG CARRIER; IMMUNOSUPPRESSIVE AGENT;

ANIMAL; ARTICLE; COMPARATIVE STUDY; DRUG EFFECT; IMMUNOLOGY; KIDNEY; MALE; RAT; T LYMPHOCYTE; THYMUS; WISTAR RAT;

ANIMALS; CYCLOSPORINE; CYCLOSPORINS; DRUG CARRIERS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; RATS; RATS, WISTAR; T-LYMPHOCYTES; THYMUS GLAND;

EID: 0030634591     PISSN: 00155632     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02819003     Document Type: Article

References (44)

1. ANTONOVYCH T.T., SABNIS S.G., AUSTIN H.A., PALESTINE A.G., BALOW J.E., NUSSENBLATT R.B., HELFRICH G.B., FOEGH M.L., ALIJANI M.R.: Cyclosporin A-induced arteriolopathy. Transplant.Proc. 20, 951-958 (1988).
2. BACH J.F., CHATENOUD L.: Immunologic monitoring of Orthoclone OKT 3-treated patients - the problem of antimonoclonal immune response. Transplant.Proc. 19, 17-20 (1987).
3. BAUMANN G.: Molecular mechanisms of immunosuppressive agents. Transplant.Proc. 24, 4-7 (1992).
4. BELNAP L.G.P., HAMMOND E.H., YOWELL R., RICHARDS K.F., REES W.V., STEVENS L.E.: Baseline biopsies define cyclosporine nephrotoxicity. Transplant.Proc. 21, 1485-1486 (1989).
5. BESCHORNER W.E., NAMNOUN J.D., HESS A.D., SHINN C.A., SANTOS G.W.: Cyclosporin A and the thymus. Amer.J.Pathol. 126, 487-496 (1987).
6. BLAIR J.T., THOMSON A.W., WHITING P.H., DAVIDSON R.J.L., SIMPSON J.G.: Toxicity of the immune suppressant cyclosporin A in the rat. J.Pathol. 138, 163-178 (1982).
7. BOREL J.F.: The cyclosporins. Transplant.Proc. 21, 810-815 (1989).
8. BRAYMAN K.L., HICKEY W.F., BARKER C.F., NAJI A.: Thymic major histocompatibility complex antigen expression and suppressor cell sparing by cyclosporine. Transplant.Proc. 19, 1181-1183 (1987).
9. BRODEHL J., OFFNER G., HOYER P.F., SCHIRG E., PICHLMAYR R., WONIGETT K.: Cyclosporin A in pediatric kidney transplantation and its effects on posttransplantation growth. Nephron 44, 26-31 (1986).
10. CURTIS J.J., LASKOW D.A.: Cyclosporine-induced nephrotoxicity - pathophysiology of decreased renal flow. Transplant.Proc. 20, 540-543 (1988).
11. DUIJVESTIJN A.M., KÖHLER Y.G., HOEFSMIT E.C.M.: Interdigitating cells and macrophages in the acute involuting rat thymus. Cell Tissue Res. 224, 291-301 (1982).
12. FARLAND E.J.M.C., SCEARCE R.M., HAYNES B.F.: The human thymic microenvironment. J.Immunol. 133, 1241-1249 (1984).
13. FLANAGAN P.A., DUNCAN R., ŘÍHOVÁ B., ŠUBR V., KOPEČEK J.: Immunogenicity of protein-N-HPMA copolymer conjugates in A/J and B 10 mice. J.Bioact.Compat.Polymers 5, 151-166 (1990).
14. GOLDSTEIN G.: Overview of Orthoclone OKT 3 - monoclonal antibody for therapeutic use in transplantation. Transplant.Proc. 19, 1-6 (1987).
15. HAMILOS D.L.: Immunocompetent dendritic cells, pp. 89-118 in J.M. Cruse, L.R. Lewis (Eds): The Year in Immunology, Vol. 3. Karger, Basel 1988.
16. HAYNES B.F., SCEARCE R.M., LOBACH D.F., HENSLEY L.L.: Pnenotypic characterization and ontogeny of mesodermal-derived and endocrine epithelial components of the human thymic microenvironment. J.Exp.Med. 159, 1149-1168 (1984).
17. JEGOROV A., ŘÍHOVÁ B., ULBRICH K., MAŤHA V., STROHALM J., FORNŮSEK L.: Targeted polymeric conjugates of cyclosporin. Czechosl.Patent Appt. PV 215-91 (1991).
18. JENKINS M.K., SCHWARTZ R.H., PARDOLL D.M.: Effects of cyclosporin A on T cell development and clonal deletion. Science 241, 1655-1658 (1988).
19. JULIUS M.H., SIMPSON E., HERZENBERG L.A.: A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur.J.Immunol. 3, 645-649 (1973).
20. KOPEČEK J.: Biodegradation of biomedical polymers, pp. 305-320 in H. Benoit, M. Rempp (Eds): IUPAC Macromolecules. Pergamon Press, Oxford 1982.
21. KREIS H., CHKOFF N., CHATENOUD L., CAMPOS H., BACH J.F., GOLDSTEIN G.: Prolonged administration of Orthoclone OKT 3 to kidney allograft recipients. Transplant.Proc. 18, 954-956 (1986).
22. LEVEY R.H., MEDAWAR P.B.: Some experiments on the action of antilymphoid sera. Proc.N.Y.Acad.Sci. 120, 164-177 (1966).
23. LÖNING T., CASELITZ J., OTTO H.F.: The epithelial framework of the thymus in normal and pathologic conditions. Virchows Arch.A Pathol.Anat. 392, 7-20 (1981).
24. MAYES J.T., THISTLETHWAITE J.R., STUART J.K., BUCKINGHAM M.R., STUART F.P.: Reexposure to OKT 3 in renal allograft recipients. Trasplantation 45, 349-353 (1988).
25. MIHATSCH M.J.: Selectivity still has its price - personal experience with cyclosporine over the last 10 years. Transplant.Proc. 24, 67-70 (1992).
26. MIHATSCH M.J., THIEL G., RYFFEL B.: Histopathology of cyclosporine nephrotoxicity. Transplant.Proc. 20, suppl. 759-771 (1988).
27. MYERS B.D., NEWTON L., BOSHKOS C., MACOVIAK J.A., FRIST W.H., DERBY G.C., PERLROTH M.G., SIBLEY R.K.: Chronic injury of human renal microvessels with low-dose cyclosporine therapy. Transplantation 46, 694-703 (1988).
28. MYERS B.D., NEWTON L., OYER P.: The case against the indefinite use of cyclosporine. Transplant.Proc. 23, 41-42 (1991).
29. MYERS B.D., ROSS J., NEWTON L., LOETSCHER L., PERLROTH M.: Cyclosporine-associated chronic nephropathy. New Engl.J.Med. 311, 699-705 (1984).
30. NAQUET P., LEPESANT H.: The role of accessory cells in positive and negative selection in the thymus, pp. 63-104 in L. Fornůsek, V. Větvička (Eds): Immune System Accessory Cells. CRC Press, Boca Raton 1992.
31. PRUD'HOMME G.J., VANIER L.E.: Cyclosporine, tolerance and autoimmunity. Clin.Immunol.Immunopathol. 66, 185-192 (1993).
32. ŘÍHOVÁ B., JEGOROV A., STROHALM J., MATHA V., ROSSMANN P., FORNŮSEK L., ULBRICH K.: Antibody-targeted cyclosporin A. J.Control.Release 19, 25-40 (1992).
33. ŘÍHOVÁ B., KOPEČEK J.: Biological properties of targetable HPMA-antibody conjugates. J.Control.Release 2, 289-310 (1985).
34. ŘÍHOVÁ B., KOPEČKOVÁ P., STROHALM J., ROSSMANN P., VĚTVIČKA V., KOPEČEK J.: Antibody-directed affinity therapy applied to the immune system. Clin.Immunol.Immunopathol. 46, 100-114 (1988).
35. ŘÍHOVÁ B., STROHALM J., PLOCOVÁ D., ULBRICH K.: Selectivity of antibody-targeted anthracycline antibiotics on T lymphocytes. J.Bioact.Compat.Polymers 5, 249-266 (1990).
36. ŘÍHOVÁ B., ULBRICH K., VĚTVIČKA V., BILEJ M., DUNCAN R., KOPEČEK J.: Histocompatibility of HPMA copolymers containing adriamycin. Biomaterials 10, 335-342 (1989).
37. ROSSMANN P., JIRKA J., CHADIMOVÁ M., RENELTOVÁ I., SAUDEK F.: Arteriolosclerosis of the human renal allograft - morphology, origin, life history and relationship to cyclosporine therapy. Virchows Arch. A Pathol.Anat. 418, 129-141 (1991).
38. ROSSMANN P., ŘÍHA I., MATOUŠOVIC K., BOHDANECKÁ M., BUKOVSKÝ A.: Experimental ablation nephropathy - fine structure, morphometry, cell membrane epitopes, glomerular polyanion, and effect of subsequent transplantation. Path.Res. Pract. 186, 491-506 (1990).
39. RYFFEL B.: Ciclosporin toxicology - experimental studies, pp. 181-187 in J.F. Borel (Ed.): Ciclosporin. Karger, Basel 1986.
40. RYFFEL B., HIESTAND P., FOXWELL B., DONATSCH P., BOELSTERLI H.J., MAURER G., MIHATSCH M.J.: Nephrotoxic and immunosuppressive potentials of cyclosporine metabolites in rats. Transplant.Proc. 18, 41-45 (1986).
41. SALOMON D.R.: An alternative view mimicking the significance of cyclosporine nephrotoxicity and in favor of enhanced immunosuppression for long-term kidney transplant recipients. Transplant.Proc. 23, 2115-2116 (1991).
42. THOMSON A.W., WHITING P.M., BLAIR J.T., DAVIDSON R.J.L., SIMPSON G.J.: Pathological changes in the rat during a 3-week course of high dosage cyclosporin A. Transplantation 32, 271-277 (1981).
43. VOLFOVÁ I., ŘÍHOVÁ B., VĚTVIČKA V., ROSSMANN P., ULBRICH K.: Biocompatibility of biopolymers. J.Bioact.Compat.Polymers 7, 175-190 (1992).
44. WILSON C.B., DIXON F.J., FORTNER J.G., CERILLI G.J.: GBM-reactive antibody in antilymphocyte globulin. J.Clin.Invest. 50, 1525-1535 (1971).